Neuraxis Inc Dossier - Source-backed chat

Neuraxis Inc

NRXSNYSE

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.30

Intrinsic Value $4.62median of 2 methodsbased on filings through 30 Jun 2026

Market Price $7.17Price as of 1 Oct 2026

OvervaluedIntrinsic value is 36% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $90M

Enterprise Value $81.9M

Shares Outstanding 12.7M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Neuraxis, Inc. (NRXS) is a first-to-market growth-stage medical technology company commercializing drug-free neuromodulation therapies (specifically its proprietary Percutaneous Electrical Nerve Field Stimulation, or PENFS, technology) for chronic gastrointestinal disorders. The investment thesis is anchored on the recent implementation of the AMA Category I CPT code (effective January 1, 2026), which significantly streamlines physician billing, increases average selling prices, and accelerates commercial insurance adoption. While the company continues to operate with a going concern warning due to historical losses, its record Q1 2026 revenue growth of 80% year-over-year and expanding gross margins (86.4%) demonstrate strong commercial traction. With a clear path to cash flow breakeven at approximately $15 million in annual revenue and a reduced cash burn rate, Neuraxis represents a high-upside opportunity in the pediatric and adult neuromodulation space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$11.00

High · most bullish analyst$13.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects prolonged friction in securing written medical policy coverage from remaining commercial payers, keeping the prior authorization approval rate depressed. Slow adoption of the Category I CPT code by hospital administrators, combined with an elevated cash burn from commercial hires, could force the company to rely heavily on its at-the-market equity facility, causing significant shareholder dilution and prolonging the going concern risk.

Base CaseCentral scenario

The base case assumes steady commercial execution of the IB-Stim device in the pediatric market, leveraging the Category I CPT code to expand active accounts across the 260 targeted children's hospitals. It also factors in early order momentum from the 180 VA hospitals under the Federal Supply Schedule (FSS) contract awarded in late 2025, alongside the resumed commercialization of the Rectal Expulsion Device (RED). Revenue is projected to scale toward the $15 million cash flow breakeven run-rate by late 2027 or 2028, with gross margins stabilizing above 86%.

Bull CaseUpside scenario

The bull case assumes rapid commercial adoption of the IB-Stim device following the Category I CPT code implementation, with covered lives expanding to 125 million and utilization reaching 0.04%, generating approximately $23.9 million in annual revenue. Additionally, it projects strong penetration into the VA health system (targeting 5,000 patients for $23.9 million) and incremental adult GI revenue of $5 million, driving the total annual run-rate to approximately $53 million.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-to-market advantage with FDA-cleared IB-Stim technology for pediatric functional abdominal pain associated with IBS, functional dyspepsia, and nausea.
Favorable regulatory and reimbursement landscape following the AMA Category I CPT code activation on January 1, 2026.
Strong margin profile with Q1 2026 gross margins expanding to 86.4% due to a favorable mix shift toward full-reimbursement payers.
Established federal footprint via the Federal Supply Schedule (FSS) contract, opening access to 180 VA hospitals for adult indications.

Key Investment Risks

Going concern risk due to historical operating losses and accumulated deficits, requiring disciplined cash management and potential equity dilution.
Payer policy execution risk, as written medical policy coverage remains essential despite having an active Category I CPT code.
High concentration of revenue on a single product line (IB-Stim) while other portfolio products like RED are in early commercialization phases.

Thesis Invalidation Triggers

Failure to achieve the $15 million annual revenue run-rate required for cash flow breakeven by 2028.
A material decline in gross margins below 80% due to pricing pressure or increased reliance on discounted patient financial assistance programs.
Inability to secure additional capital or execute on the ATM facility, leading to severe liquidity constraints.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.